Related Experiment Video
Updated: Jan 9, 2026
09:14
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
11.4K
Nirsevimab Effectiveness Against RSV-Related Hospitalisations in Children Under 24 Months: A Test-Negative
Vânia Gaio1,2, Camila Henriques3, Miguel Lança3,4
1Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.
Influenza and Other Respiratory Viruses
|December 1, 2025
Summary
Nirsevimab effectively reduced hospitalizations from respiratory syncytial virus (RSV) by 78.5% in infants under two years old. This study supports Nirsevimab
Area of Science:
- Pediatrics
- Immunology
- Public Health
Background:
- Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations.
- Effective immunization strategies are crucial for preventing severe RSV disease in vulnerable populations.
Purpose of the Study:
- To evaluate the real-world effectiveness of Nirsevimab in preventing RSV-related hospitalizations in infants.
- To provide evidence supporting public health decisions regarding RSV immunisation.
Main Methods:
- A test-negative case-control design was employed within the VigiRSV network.
- Data were collected from eligible children under two years of age between weeks 43/2024 and 16/2025.
- 341 participants were included, with 137 testing positive for RSV.
Main Results:
- Adjusted Nirsevimab effectiveness (NE) against RSV-related hospitalization was 78.5% (95% CI: 59.3-89.0).
- The study population consisted primarily of healthy infants (91.2% without chronic conditions).
- Sensitivity analyses confirmed the robustness of the findings.
Conclusions:
- Nirsevimab demonstrates significant effectiveness in preventing RSV-related hospitalizations in a predominantly healthy infant population.
- These findings support the use of Nirsevimab for RSV immunisation programs.
- The study contributes valuable data for informing public health strategies against RSV.
More Related Videos
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.1K
01:51Vaccinations
51.1K
Overview
51.1K
01:30Pneumonia V: Nursing management and Prevention
3.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K